首页> 美国卫生研究院文献>OncoTargets and therapy >Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials

【2h】

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials

机译：血管内皮生长因子受体酪氨酸激酶抑制剂治疗晚期甲状腺癌的有效性和安全性：一项随机对照试验的荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundWe performed a systematic review and meta-analysis to determine the efficacy and safety of the US Food and Drug Administration approved vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) in the treatment of advanced thyroid cancer.

机译：背景我们进行了系统的综述和荟萃分析，以确定美国食品和药物管理局批准的血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFR-TKIs）在治疗晚期甲状腺癌中的疗效和安全性。

著录项

期刊名称 OncoTargets and therapy
作者
Wufuer Yimaer; Aizizi Abudouyimu; Ye Tian; Sailike Magaoweiya; Duman Bagedati; Hao Wen;
展开▼
作者单位

展开▼
年(卷),期 2016(9),-1
年度 2016
页码 1167–1173
总页数 7
原文格式 PDF
正文语种
中图分类应用微生物学;肿瘤学;
关键词
angiogenesis inhibitors toxicity clinical trials thyroid cancer meta-analysis;

机译：血管生成抑制剂;毒性;临床试验;甲状腺癌;荟萃分析;

相似文献

外文文献
中文文献
专利

1. 表皮生长因子受体酪氨酸激酶抑制剂联合化疗治疗晚期肺腺癌的疗效及安全性分析 [J] . 马晓, 张帅, 崔斌, 癌症（英文版） . 2019,第011期
2. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials [J] . Wufuer Yimaer, Aizizi Abudouyimu, Ye Tian, OncoTargets and therapy . 2016,第6期

机译：血管内皮生长因子受体酪氨酸激酶抑制剂治疗晚期甲状腺癌的有效性和安全性：一项随机对照试验的荟萃分析
3. The role of vascular epithelial growth factor receptor-tyrosine kinase inhibitors in the treatment of advanced breast cancer: A meta-analysis of 12 randomized controlled trials [J] . LiJ., HuangS., ZhengW., Current medical research and opinion . 2013,第12期

机译：血管上皮生长因子受体酪氨酸激酶抑制剂在晚期乳腺癌治疗中的作用：12项随机对照试验的荟萃分析
4. Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials [J] . Shaodong Hong, Wenfeng Fang, Wenhua Liang, OncoTargets and therapy . 2014,第4期

机译：血管内皮生长因子受体酪氨酸激酶抑制剂治疗相关死亡的风险：41项随机对照试验的荟萃分析
5. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
6. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
7. Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials [O] . Shaodong Hong, Wenfeng Fang, Wenhua Liang, 2014

机译：血管内皮生长因子受体酪氨酸激酶抑制剂治疗相关死亡的风险：41项随机对照试验的荟萃分析
8. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials [O] . Hao Wen, Wufuer Yimaer, Aizizi ABuDuReYiMu, 2016

机译：血管内皮生长因子受体酪氨酸激酶抑制剂治疗晚期甲状腺癌的疗效和安全性：随机对照试验的荟萃分析

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials

摘要

著录项

相似文献

相关主题

期刊订阅